Skip to main content

IGC Pharma, Inc.

corporate_fare Company Profile

IGC Pharma, Inc.

IGC·NASDAQ·Life Sciences·CIK 0001326205

IGC Pharma, Inc. is a life sciences company focused on improving the lives of individuals affected by Alzheimer's disease by addressing both its symptoms and the disease itself. Its near-term focus is advancing IGC-AD1, its lead drug candidate, which is in Phase 2 clinical trials targeting agitation in Alzheimer's patients. IGC-AD1 has completed preclinical evaluations and a successful Phase 1 safety trial and is being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial officially named "CALMA" (Calming Agitation in Alzheimer's). Interim data have shown patients receiving IGC-AD1 experienced a statistically significant reduction in agitation compared to placebo within the first 2-6 weeks of treatment, and interim data also demonstrate a clinical and statistically significant reduction in sleep disturbances among Alzheimer's patients receiving the active medication compared to placebo. The company is also investing in an early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models designed to identify early markers of Alzheimer's. It leverages an internal contract research organization to advance its pipeline. During fiscal 2025, the company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences and determined that it operates as a single reportable segment, focused on the vision to make the world free from Alzheimer's. Historically, the company reported two operating segments: Life Sciences and Infrastructure.

IGC Pharma, Inc. (NASDAQ:IGC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for IGC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Recent SEC coverage for IGC spans 10-Q.

Recent high-impact activity:

  • IGC Pharma Narrows Q3 Loss, but Cash Falls to $377K Ahead of CALMA Topline

Financial Snapshot

Fiscal year ended March 31, 2025
Revenue
$1.27M
Net Income
-$7.12M
Diluted EPS
-$0.09
Op. Cash Flow
-$4.79M
Free Cash Flow
-$4.91M
Gross Profit
$619K
Operating Income
-$7.45M
Cash & Equivalents
$405K
Total Debt
$137K
Debt / Equity
0.02×
Net Margin
-5.60×
Shares Outstanding
80.88M sh
Source: 10-K · filed 2025-06-27 · accession 0001185185-25-000706

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 395,551 shares in IGC as of the October 30, 2026 settlement, a 37.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 27.1% of IGC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)395,551 shares as of October 30, 2026
Change vs prior period▼ 37.8%
Days to cover1.00 at avg daily volume of 508,862
Daily short volume (FINRA facilities)27.1% of 304,557 shares on November 20, 2026
5-day average short volume36.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.17 +1.19% today
52-week range · as of 2026-11-06 $0.08 – $0.4041
Market cap
$19.6M
Volume
514.2K (1.0× avg)
3-mo avg 503.3K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IGC - Latest Insights

IGC
Nov 06, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.200
Real-time Price: $0.170 info
Change: -$0.030 (-15%) info
Market Cap: $19.603M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets